Haemonetics Corporation (HAE)
| Market Cap | 3.20B |
| Revenue (ttm) | 953.22M |
| Net Income (ttm) | 22.59M |
| Shares Out | 51.11M |
| EPS (ttm) | 0.84 |
| PE Ratio | 74.45 |
| Forward PE | 21.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,734 |
| Open | 60.25 |
| Previous Close | 60.77 |
| Day's Range | 60.25 - 63.55 |
| 52-Week Range | 43.50 - 75.34 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 72.42 (+15.8%) |
| Earnings Date | May 10, 2022 |
About HAE
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides autom...
Financial Performance
In 2021, Haemonetics's revenue was $870.46 million, a decrease of -11.94% compared to the previous year's $988.48 million. Earnings were $79.47 million, an increase of 3.85%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HAE stock is "Buy." The 12-month stock price forecast is 72.42, which is an increase of 15.80% from the latest price.
News
Here's Why Investors Should Retain Haemonetics (HAE) For Now
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics to Host Investor Day Event on June 29, 2022
BOSTON , May 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that it will host an Investor Day in Boston on Wednesday, June 29, 2022 beginning at 10:00 AM EDT. Members of Haemonet...
Haemonetics 4th Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , May 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2022, which ended April 2, 20...
3 Medical Product Stocks Set to Beat on Earnings This Season
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2022 Results: May 10, 2022
BOSTON, April 6, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2022 financial results at 6:00 am EDT on Tuesday, May 1...
Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay
Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.
Haemonetics Appoints James D'Arecca Chief Financial Officer
BOSTON , March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective A...
Haemonetics (HAE) Up 4.4% Since Last Earnings Report: Can It Continue?
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.
Haemonetics to Present at Raymond James 43rd Annual Institutional Investors Conference
BOSTON, Feb. 23, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 43rd Annu...
Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss
Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.
Why Haemonetics Shares Are Trading Higher Today?
Haemonetics Corporation HAE posted Q3 FY22 sales of $259.77 million, +8% Y/Y, missing the consensus of $ $266.74 million. Organic revenue was down 0.8%.
Haemonetics (HAE) Q3 Earnings Beat Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics 3rd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website
BOSTON, Feb. 8, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2022, which ended January 1, 2022, are available on its Investor Re...
Should You Buy Haemonetics (HAE) Ahead of Earnings?
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Haemonetics (HAE) Expected to Beat Earnings Estimates: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2022 Results: February 8, 2022
BOSTON, Jan. 5, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, Februar...
Here's Why You Should Retain Haemonetics (HAE) Stocks for Now
Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.
Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows
Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.
Why Haemonetics Stock Dived by 15% Today
The company broadly meets expectations for its Q2 2022 but trims its full-year guidance.
Haemonetics (HAE) Lags Q2 Earnings and Revenue Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of -4.76% and -2.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?